TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00531336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib (Macugen)
Description: 0.3 mg intravitreally applied every 6 weeks as long as required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaptanib (Macugen)
Description: 0.3 mg intravitreally applied every 6 weeks as long as required
Study: NCT03831542

Intervention type: BEHAVIORAL
Intervention: direct follicular aspiration
Description: direct follicular aspiration

Intervention type: BEHAVIORAL
Intervention: follicular flushing
Description: follicular flushing
Study: NCT02417441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eeva
Description: Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
Study: NCT01489852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17beta-estradiol
Description: Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Study: NCT03428399

Intervention type: OTHER
Intervention: Psychosocial variables
Description: The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
Study: NCT00162097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz containing antiretroviral regimen
Description: Capsule or Tablet, Oral, once daily for 2 days
Study: NCT01411514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets. They will be administered during 25 days
Study: NCT03420287

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MPM Prepared From Allogenic Bone Graft
Description: patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone
Description: patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
Study: NCT05103306

Intervention type: DRUG
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor

Intervention type: DRUG
Intervention: INS
Description: Basal insulin add on the background OADs
Study: NCT04324528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vv-ECMO + cytokine adsorption (Cytosorb adsorber)
Description: in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)
Study: NCT03567044

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
Study: NCT01252355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for teriflunomide)
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-beta (IFN-beta)
Description: Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta)
Description: Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert.
Study: NCT00538772

Intervention type: OTHER
Intervention: Not applicable - blood tests/tissue specimen tests will be undertaken
Description: Not applicable - blood tests/tissue specimen tests will be undertaken
Study: NCT02566564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopain
Description: intra-articular injection
Study: NCT02330770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa and HCG
Description: Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa then HCG (single low-dose)
Description: Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
Study: NCT04324528

Intervention type: DEVICE
Group type: OTHER
Intervention: vv-ECMO only (no cytokine adsorption)
Description: COVID-19-diseased treated with vv-ECMO
Study: NCT02330770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRHa then HCG (multiple low-doses)
Description: Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
Study: NCT00520624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle strength training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle strength training

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT04812743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Health Research Champions
Description: 20 Colorectal Health Research Champions will be recruited from the VCU Massey Cancer Center Catchment Area (66 counties in Virginia) The Colorectal Health Research Champions will receive training in four specific areas during group educational sessions.~Colorectal Health Research Champions will be asked to disseminate the four defined messages on at least two occasions to small groups in their social network in a venue of their choice (house chats, faith-based, social gatherings, family gatherings, etc.). We ask that each CHRC participant host 2 chats with 5-10 people in attendance at each chat. We expect that at least 200 participants will be invited to chats through 10 CHRCs.
Study: NCT05398549

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Subjects in group A was treated with conventional physical therapy i.e. grade 1 and 2 mobilization and stretching exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: group B was treated with virtual reality stimulation given for 30 minutes per session through kinetic Xbox with sensory accelerator model no.1414. Two traditional training activities was used to improve shoulder Range of motion i.e. badminton and American baseball activity 12 times of the training.
Study: NCT02520583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactic acid bacteria and bifidobacteria

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04162002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft
Description: Filler Injection
Study: NCT04046458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nighttime Vital Sign EHR Alert
Description: A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No EHR alert
Description: No change to EHR function; no alert visible to providers
Study: NCT03805776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting (diet restruction for specific period)
Description: 12-14 hours fasting
Study: NCT04867447

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological trauma evaluation
Description: Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE).

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological trauma evaluation
Description: Psychological trauma exposure is assessed by validated scales:~* Childhood Trauma Questionnaire (CTQ)~* Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)~* Cumulative Trauma Scale.~* The Holmes and Rahe Stress Scale.~Other clinical scales used:~* Positive and Negative Syndrome Scale (PANSS).~* Dissociative Experiences Scale (DES)~* Mini-Mental State Examination (MMSE).
Study: NCT03423927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis + Self-care
Description: Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
Study: NCT03600415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low altitude: 470m above sea level
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Säntis; 2500m above sea level
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT00930345

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib (SUTENT)
Description: Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator.
Study: NCT04382235

Intervention type: DEVICE
Intervention: Non-invasive ventilatory support
Description: All non-invasive ventilatory support wll be recorded. All collected data is taken and monitored during normal clinical practice without adding any other tests.
Study: NCT01061099

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
Study: NCT03099252

Intervention type: OTHER
Intervention: Parent-targeted BSweet2Babies video
Description: The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
Study: NCT02656589

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)

Intervention type: DRUG
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)

Intervention type: DRUG
Intervention: Trastuzumab
Description: patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle

Intervention type: DRUG
Intervention: Trastuzumab
Description: patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
Study: NCT00813722

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: phone call
Description: patients received or not phone calls to give orientation abou treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: phone call
Description: patients received or not phone calls to give orientation abou treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine (calcium chanel blocker) and losartan (at1 antagonist)
Description: 2,5 mg tid and 25 mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atenolol (beta blocker) and hydrochlorothiazide (diuretic)
Description: 25 mg tid and 12,5 mg tid
Study: NCT03321279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive
Description: Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
Study: NCT03450499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: the analgesic affects of ketamine will be compared between the experimental and placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the analgesic requirement will be calculated in placebo group.
Study: NCT03506659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUDO-SCAN Device
Description: Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SUDO-SCAN Device
Description: Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
Study: NCT04726774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Two sessions of hypnosis, about 30 minutes each, weekly provided, by a physician trained in medical hypnosis.~Each session was realized as possible during walking, according to the agreement and the physical status of the participant.~Each sessions of hypnosis includes 3 phases : induction, walk perception alteration and post-hypnotic suggestion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Intensive physiotherapy for 2 weeks, with walking and balance exercises, (individual and group exercises). Education of risk of falling and prevention of falls.
Study: NCT04177966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pre-prepared video describing the cesarean surgery
Description: a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: general information
Description: In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
Study: NCT00797394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of 2007RD01 and saw palmetto lipidic extract
Description: Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saw palmetto lipidic extract
Description: Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
Study: NCT00332774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic solution 0.1%
Description: 1 drop 4 times daily for 90 days
Study: NCT01389089

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: ice gel pack
Description: ice gel pack combined with elevation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-layer compression bandage
Description: Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
Study: NCT00332774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine ophthalmic solution 0.4%
Description: 1 drop 4 times daily for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac ophthalmic suspension vehicle
Study: NCT03812263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L201
Description: CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
Study: NCT04708899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: arabic version of differential processing training program
Description: comprehensive training program for central auditory processing disorder contains auditory and linguistic tasks (language organization, phonemic and phonetic awareness, dichotic listening,temporal patterning and auditory discrimination).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arabic computer based auditory traing program(CBAT)
Description: comprehensive computer based traing program for central auditory processing disorder contains auditory memory, temporal processing, dichotic listening , selective attention and phonemic awareness games.
Study: NCT03280706

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Maltodextrin 50g in water 500ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange Juice
Description: Orange juice 480ml + 20ml of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee with milk
Description: Coffee with milk (330 ml of milk + 220 of water)
Study: NCT00478088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoDisc
Description: The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrumented Anterior Cervical Discectomy and Fusion (ACDF)
Description: Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
Study: NCT01543737

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3ml hyaluronic acid (DUROLANE)
Description: DUROLANE Hyaluronic acid 20mg/ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2ml hyaluronic acid, (HYALGAN)
Description: HYALGAN Hyaluronic acid 10mg/ml
Study: NCT02084017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena (Negative Pressure Wound Therapy Device)
Description: No other details required.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing
Study: NCT02081001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novo Nordisk GlucaGen®
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Nordisk GlucaGen®
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pump™ (glucagon infusion)
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pump™ (glucagon infusion)
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg